Sometimes a wearing off effect may occur at the end of the dosing interval, where a patient may feel Parkinson's symptoms.
On March 31, 2010, the United States Food and Drug Administration stated it is evaluating long-term clinical data from STRIDE-PD which found that a greater number of patients taking Stalevo had prostate cancer compared to those taking carbidopa/levodopa [REF].